NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

Glencore plc (OTCMKTS: GLNCY, GLCNF) Class Period: September 30, 2016 to July 2, 2018 Lead Plaintiff Deadline: September 7, 2018

The lawsuit alleges that throughout the class period, Glencore plc made materially false and/or misleading statements and/or failed to disclose that: (i) Glencore’s conduct would subject it to heightened scrutiny by U.S. and foreign government bodies resulting in investigations into the company’s compliance with money laundering and bribery laws, as well as the Foreign Corrupt Practices Act; and (ii) as a result, defendants’ statements about Glencore’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.    

On May 18, 2018, Bloomberg reported that the U.K.'s Serious Fraud Office was preparing to open a formal bribery investigation into Glencore. Then on July 3, 2018, Glencore disclosed that the U.S. Department of Justice issued its subsidiary a subpoena to produce documents and other records in connection with its compliance with U.S. money laundering statutes and the Foreign Corrupt Practices Act. 

Get additional information about the GLNCY lawsuit: http://www.kleinstocklaw.com/pslra-c/glencore-plc?wire=3

Sibanye Gold Limited (NYSE: SBGL) Class Period: April 7, 2017 to June 26, 2018 Lead Plaintiff Deadline: August 27, 2018

The lawsuit alleges that Sibanye Gold Limited made materially false and/or misleading statements and/or failed to disclose that: (1) Sibanye’s safety protocols were inadequate to prevent a high rate of worker death; (2) Sibanye’s mining supervisors routinely forced Company employees to work in unsafe and unlawful conditions; the foregoing issues would foreseeably subject Sibanye to heightened regulatory oversight; and (3) as a result, Sibanye’s public statements were materially false and misleading at all relevant times.

Get additional information about the SBGL lawsuit: http://www.kleinstocklaw.com/pslra-c/sibanye-...ted?wire=3

Newell Brands Inc. (NYSE: NWL) Class Period: February 6, 2017 to January 24, 2018 Lead Plaintiff Deadline: August 20, 2018

The complaint alleges that during the class period Newell Brands Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s retail channel was loaded with extremely high levels of unsold Newell product; (ii) contrary to defendants’ representations, the build-up of Newell inventory in the retail channel was due to Company-specific rather than macroeconomic reasons; (iii) as a result of the unusually high levels of unsold inventory in the retail channel, Newell was exposed to a heightened risk that it would experience slower sales growth in future periods; and (iv) undisclosed managerial and cultural differences in the legacy Newell and Jarden businesses had created significant discord that was having a material adverse effect on the Company’s operating performance.

Get additional information about the NWL lawsuit: http://www.kleinstocklaw.com/pslra-c/newell-b...inc?wire=3

Flex Pharma, Inc. (NASDAQ: FLKS) Class Period: November 6, 2017 to June 12, 2018 Lead Plaintiff Deadline: August 20, 2018

The lawsuit alleges that Flex Pharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and (ii) as a result, Flex's public statements were materially false and misleading at all relevant times.

On June 13, 2018, Flex announced that it planned to halt its FLX-787 trials, citing oral tolerability concerns observed in both studies. Flex also said that it will restructure its organization to reduce costs, including reducing its workforce by approximately 60%, and that Flex's Board is exploring "strategic alternatives, including the potential sale or merger of the company." Following this news, Flex stock dropped $3.14 per share, or 75.12%, to close at $1.04 on June 13, 2018.

Get additional information about the FLKS lawsuit: http://www.kleinstocklaw.com/pslra-c/flex-pharma-inc?wire=3

Facebook, Inc. (NASDAQ: FB) Class Period: October 1, 2017 to July 26, 2018 Lead Plaintiff Deadline: September 25, 2018

The complaint alleges that throughout the class period Facebook, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the implementation of the General Data Protection Regulation (“GDPR”), which was adopted by the European Union on or around April 14, 2016, would have a foreseeable and materially negative impact on use of the Platform, revenue growth, and profitability because the informed consent required by the GDPR resulted in many users rejecting Facebook’s privacy policies and/or procedures and exposed a significant number of fake accounts on the platform; (ii) by May 25, 2018, Facebook’s Platform use and revenue growth had already begun to decline as a result of Facebook’s efforts to comply with the GDPR; (iii) the decline in Facebook’s Platform use and the increase in costs as a result of complying with the GDPR had a materially adverse effect on Facebook’s financial health, including its revenue and projected growth; and (iv) as a result, Facebook’s public statements were materially false and misleading at all relevant times.

Get additional information about the FB lawsuit: http://www.kleinstocklaw.com/pslra-c/facebook-inc-3?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com